These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7628988)

  • 1. In-vitro antimicrobial activity of the new fluoroquinolone, grepafloxacin, against pathogenic Nocardia spp.
    Yazawa K; Mikami Y
    J Antimicrob Chemother; 1995 Apr; 35(4):541-4. PubMed ID: 7628988
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro susceptibility of Nocardia spp. to a new fluoroquinolone, tosufloxacin (T-3262).
    Yazawa K; Mikami Y; Uno J
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2140-1. PubMed ID: 2619279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of grepafloxacin against Haemophilus influenzae and Moraxella catarrhalis.
    Maskell JP; Whiley AC; Sefton AM
    Eur J Clin Microbiol Infect Dis; 1998 Apr; 17(4):293-5. PubMed ID: 9707317
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)).
    Sewell DL; Barry AL; Allen SD; Fuchs PC; Murray PR; Tenover FC
    J Antimicrob Chemother; 1996 Jan; 37(1):139-43. PubMed ID: 8647755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
    Ridgway GL; Salman H; Robbins MJ; Dencer C; Felmingham D
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of grepafloxacin against respiratory isolates of Streptococcus pneumoniae.
    Johnson AP; Warner M; Parsons T
    Eur J Clin Microbiol Infect Dis; 1997 Aug; 16(8):622-3. PubMed ID: 9323481
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.
    Marco F; Jones RN; Hoban DJ; Pignatari AC; Yamane N; Frei R
    J Antimicrob Chemother; 1994 Mar; 33(3):647-54. PubMed ID: 8040130
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
    Ikejima H; Yamamoto H; Ishida K; Kaku M; Shimada J
    J Infect Chemother; 2000 Sep; 6(3):148-50. PubMed ID: 11810555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of OPC-17116 against bacterial enteric pathogens.
    Arduino RC; Frosolono M; Murray BE
    J Antimicrob Chemother; 1994 Sep; 34(3):403-7. PubMed ID: 7829414
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthesis of possible metabolites of 1-cyclopropyl-1,4-dihydro-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)- 4-oxo-3-quinolinecarboxylic acid (Grepafloxacin, OPC-17116).
    Morita S; Otsubo K; Matsubara J; Ohtani T; Kawano Y; Ohmori K; Ohguro K; Uchida M
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2246-52. PubMed ID: 8582026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
    Prats G; Roig C; Miró E; Navarro F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):328-34. PubMed ID: 12072950
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW; Wexler HM
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
    Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T
    Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Kawamura T; Takahashi Y; Okezaki E; Nagata O; Kato H; Kawada Y
    J Antimicrob Chemother; 1997 Dec; 40(6):907-9. PubMed ID: 9462448
    [No Abstract]   [Full Text] [Related]  

  • 20. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.